On February 27, 2026, the EMA’s Committee for Medicinal Products for Human Use recommended acoziborole for treating early and ...
Morning Overview on MSN
How the ‘holy grail’ weight loss pill finally happened and what’s next
The FDA’s approval of Wegovy on June 4, 2021, ended a seven-year drought in new obesity treatments and set off a chain reaction that has reshaped how doctors, patients, and insurers think about excess ...
Which is better absorbed by the body: magnesium spray or pills? Learn which supplement option is most effective for raising magnesium levels and how to choose between them.
For use outside the EU, the regulator backed a single-dose oral approach that treats all stages and could spare patients ...
European drug regulators are endorsing a new and simpler treatment for sleeping sickness, in what could be a giant boost to efforts to eliminate the disease. A European Medicines Agency ...
A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year ...
Prosecutors portrayed a Utah mother and children’s book author as a money-hungry killer Monday on the first day of a murder trial in her husband’s death, while her defense team urged jurors not to ...
AS SHE KISSED her kids goodnight, Abby House crept out of their bedroom itching to get her next fix. Rummaging around under ...
Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a hormone called glucose-dependent insulinotropic polypeptide (GIP) to “help break ...
A doctor shared the scary story of what happened when he took his sleep medicine before bed, and viewers of the viral video said it unlocked a "new fear." According to Pescatore, he arrived home last ...
Positive phase 2 results from Jiangsu Hengrui Pharmaceuticals (JNGHF)(JHPCY) and privately held Kailera Therapeutics for their daily oral GLP-1/GIP receptor dual agonist peptide ribupatide for obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results